Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.77EUR
4:38pm GMT
Change (% chg)

€-0.89 (-1.19%)
Prev Close
€74.66
Open
€74.15
Day's High
€74.82
Day's Low
€73.77
Volume
2,008,093
Avg. Vol
2,058,521
52-wk High
€92.97
52-wk Low
€72.63

Latest Key Developments (Source: Significant Developments)

Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents
12:30pm GMT 

Dec 14 (Reuters) - Mylan Nv ::MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS.MYLAN SAYS U.S. PTAB INSTITUTED IPR PROCEEDINGS ON CLAIMS AGAINST 2 ORANGE BOOK-LISTED PATENTS OWNED BY SANOFI FOR LANTUS 100 UNITS/ML.  Full Article

Sanofi says to rely more on immunology to meet long term targets
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Sanofi ::CEO Olivier Brandicourt says the company is "on track" regarding the planned sale of its European generic drugs unit.says the company will rely more on immunology to meet its long term financial targets following setbacks with cholesterol drug Praluent and dengue vaccine Dengvaxia.  Full Article

Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma
Wednesday, 13 Dec 2017 

Regeneron Pharmaceuticals Inc ::REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC SAYS SAFETY PROFILE IN STUDY WAS GENERALLY CONSISTENT WITH APPROVED ANTI-PD-1 AGENTS..REGENERON PHARMACEUTICALS INC SAYS SUBMISSION TO EUROPEAN MEDICINES AGENCY (EMA) IS ALSO EXPECTED TO BE COMPLETED IN Q1 OF 2018.REGENERON PHARMACEUTICALS - ‍SUBMISSION TO U.S. FOOD AND DRUG ADMINISTRATION , WHICH HAS BEEN INITIATED AND IS EXPECTED TO BE COMPLETED IN Q1 OF 2018​.  Full Article

Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-Stage Trials
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Sanofi Sa ::SANOFI EXPLORES COMBINATION TREATMENTS FOR MULTIPLE MYELOMA IN NEW LATE-STAGE TRIALS.SANOFI - PHASE 3 TRIALS WILL EVALUATE ISATUXIMAB, AN ANTI-CD38 ANTIBODY, IN COMBINATION WITH OTHER CANCER TREATMENTS.  Full Article

EMA says Sanofi's dengue vaccine currently being reviewed, to take new data into account
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Sanofi ::European Medicines Agency says in emailed statement Sanofi's dengue vaccine is currently being reviewed for a central marketing authorisation by the Agency's Committee for Medicinal Products for Human Use (CHMP).EMA says any emerging data will be taken into account during assessment of Dengvaxia.  Full Article

Sanofi Ends Development Of Clostridium Difficile Vaccine
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Sanofi Sa ::SANOFI ENDS DEVELOPMENT OF CLOSTRIDIUM DIFFICILE VACCINE.SANOFI - IDMC FOR PHASE III CDIFFENSE CLINICAL TRIAL PROGRAM CONCLUDED THAT PROBABILITY THAT STUDY WILL MEET ITS PRIMARY OBJECTIVE IS LOW.SANOFI - HAS DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ITS EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE.SANOFI - SANOFI PASTEUR, VACCINES BUSINESS OF SANOFI RESPONSIBLE FOR PROGRAM, IS INFORMING INVESTIGATORS, REGULATORY AUTHORITIES & TRIAL ETHICS COMMITTEES.SANOFI - INVESTIGATORS ARE NOTIFYING STUDY VOLUNTEERS OF DECISION TO STOP PROGRAM.SANOFI - TO DISCONTINUE CLINICAL DEVELOPMENT OF EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE, TO FOCUS ON 6 VACCINE PROJECTS CURRENTLY IN DEVELOPMENT.SANOFI - ‍DATA FROM ALL VACCINATED VOLUNTEERS WILL CONTINUE TO BE ANALYZED FOR MORE INFORMATION & SHARED WITH SCIENTIFIC COMMUNITY​.  Full Article

Sanofi Ends Development Of Clostridium Difficile Vaccine
Friday, 1 Dec 2017 

Dec 1 (Reuters) - SANOFI ::REG-SANOFI ENDS DEVELOPMENT OF CLOSTRIDIUM DIFFICILE VACCINE.‍INDEPENDENT DATA MONITORING COMMITTEE (IDMC) FOR PHASE III CDIFFENSE CLINICAL TRIAL PROGRAM CONCLUDED THAT PROBABILITY THAT STUDY WILL MEET ITS PRIMARY OBJECTIVE IS LOW​.‍DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ITS EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE​.  Full Article

Aralez Announces Departure Of Chief Financial Officer
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍SCOTT J. CHARLES, CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY​.ARALEZ PHARMACEUTICALS INC - MICHAEL KASETA WILL ASSUME POSITION OF INTERIM CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍ PRIOR TO JOINING ARALEZ, KASETA SERVED AS CFO OF SANOFI NORTH AMERICA, GLOBAL SERVICES​.  Full Article

Sanofi to book 100 mln eur charge in Q4, confirms 2017 business net income guidance
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Sanofi Sa ::SANOFI UPDATES INFORMATION ON DENGUE VACCINE.SANOFI - ‍NEW ANALYSIS OF LONG-TERM DENGVAXIA DATA FOUND DIFFERENCES IN VACCINE PERFORMANCE BASED ON PRIOR DENGUE INFECTION​.SANOFI SAYS IMPACT ON BUSINESS NET INCOME STILL UNDER ASSESSMENT BUT EXPECTED TO BE IN THE RANGE OF 100 MILLION EUR AFTER TAX.SANOFI SAYS WILL RECORD THE CHARGE REFLECTING DEPRECIATION OF INVENTORIES AS WELL AS ACCELERATED DEPRECIATION OF SOME TANGIBLE AND INTANGIBLE ASSETS IN ITS Q4 RESULTS.SANOFI SAYS CONFIRMS 2017 GUIDANCE.  Full Article

Teva Appoints Michael McClellan as CFO
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES NEW ORGANIZATION STRUCTURE AND LEADERSHIP CHANGES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍COMMERCIAL BUSINESS WILL NO LONGER HAVE TWO SEPARATE GLOBAL GROUPS FOR GENERICS AND SPECIALTY MEDICINES​.TEVA PHARMACEUTICAL-‍FORMER GENERIC RESEARCH AND DEVELOPMENT, SPECIALTY RESEARCH AND DEVELOPMENT ORGANIZATIONS TO BE COMBINED INTO 1 GLOBAL GROUP WITH OVERALL RESPONSIBILITY FOR ALL RESEARCH AND DEVELOPMENT ACTIVITIES.TEVA - ‍AS A RESULT OF THE CHANGES, MICHAEL HAYDEN, ROB KOREMANS AND DIPANKAR BHATTACHARJEE WILL RETIRE FROM TEVA, EFFECTIVE DECEMBER 31​.TEVA PHARMACEUTICAL - ‍ COMMERCIAL BUSINESS WILL BE INTEGRATED INTO ONE COMMERCIAL ORGANIZATION​.TEVA - ‍MICHAEL MCCLELLAN APPOINTED EVP, CFO,WILL OVERSEE FINANCE GROUP, BUSINESS DEVELOPMENT, INVESTOR RELATIONS,INFORMATION TECHNOLOGY​.TEVA PHARMA - COMMERCIAL ‍STRUCTURE TO RELY ON 1 SUPPORTING ORGANIZATIONAL INFRASTRUCTURE INCLUDING FINANCE, LEGAL, HR, GLOBAL BRAND & COMMUNICATIONS​.TEVA PHARMACEUTICAL SAYS ‍ALREADY WORKING ON A DETAILED RESTRUCTURING PLAN FOR TEVA AND WILL SHARE IT IN MID-DECEMBER​.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍PRIOR TO JOINING TEVA, MICHAEL MCCLELLAN WAS U.S. CFO AT SANOFI​.  Full Article

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

* MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS